Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation

Klompenhouwer, Elisabeth G.; Dresen, Raphaëla C.; Verslype, Chris; Laenen, Annouschka; Hertogh, Gert De; Deroose, Christophe M.; Bonne, Lawrence; Vandevaveye, Vincent; Maleux, Geert

doi:10.1007/s00270-017-1739-5

Cited by 20 publications

(27 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On evaluation of the three trials, there were significant study limitations, such as unmet predetermined sample sizes and inconsistent and imprecise results, probably due to differences in the study populations, BCLC stage, and reported outcomes [76]. However, in a study examining patients' refractory to TACE, 36.7% patients underwent SIRT and demonstrated a response on imaging, with 10% successfully downstaged and receiving a liver transplantation [77].…”

Section: Intermediate Stage (B)mentioning

confidence: 99%

Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update

Kishore

Bajwa

Madoff

2020

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) represents a significant contributor to cancer-related morbidity and mortality with increasing incidence in both developing and developed countries. Embolotherapy as a locoregional therapeutic strategy consists of trans-arterial or “bland” embolization (TAE), trans-arterial chemoembolization (TACE), and selective internal radiotherapy (SIRT). Trans-catheter arterial therapies can be applied along all stages of HCC, either as an alternative or neoadjuvant to surgical resection/transplantation in very early and early stage HCC or as a palliative option for local disease control in unresectable and advanced stage HCC. In advanced stage HCC, SIRT did not demonstrate superiority in comparison to systemic treatment options in several recent large prospective trials, though for carefully selected patients, may confer improved tolerability with similar disease control rates. The latest embolotherapeutic techniques and literature as they pertain to the management of HCC, as well as future directions, are reviewed in this article.

show abstract

Section: Intermediate Stage (B)mentioning

confidence: 99%

Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update

Kishore

Bajwa

Madoff

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…On the other hand, DEB-TACE is associated with a risk of severe complications, including acute cholecystitis (3.3%), acute pancreatitis (5%), and gastric ulcers (3.3%) due to strong embolization (17). There have also been reports of fatal pulmonary embolus (18), liver abscess, and bile leakage (19) caused by small beads (40-120 μm) that passed through a blood flow shunt or of overdose in association with beads.…”

Section: Discussionmentioning

confidence: 99%

Huge Hepatocellular Carcinoma Treated with Radical Hepatectomy after Drug-eluting Bead Transarterial Chemoembolization

et al. 2019

View full text Add to dashboard Cite

We performed split drug-eluting bead transarterial chemoembolization (DEB-TACE) in a patient with huge unresectable hepatocellular carcinoma and multiple intrahepatic metastases. However, TACE was discontinued at the fourth application because the tumor was fed by the cholecystic artery. As most intrahepatic metastases disappeared following DEB-TACE, the patient was able to undergo radical hepatectomy, and has maintained a complete response. DEB-TACE enables cancer treatment without reducing the liver or renal function. However, it is associated with a risk of ischemia in other organs in patients whose arteries feed both tumors and other organs; thus appropriate selection is required.

show abstract

“…71 However, in a study examining patients refractory to TACE, 36.7% patients underwent SIRT and demonstrated a response on imaging, with 10% successfully downstaged received liver transplantation. 72…”

Section: Downstage To Transplantmentioning

confidence: 99%

Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions

Bajwa

Madoff

Kishore

2020

Digestive Disease Interventions

View full text Add to dashboard Cite

Primary and secondary liver cancers are a major cause of mortality worldwide. Transarterial liver-directed therapy, or embolotherapy, represents an important locoregional treatment strategy for primary and secondary liver tumors. Embolotherapeutic modalities include bland embolization (transarterial embolization), chemoembolization (transarterial chemoembolization), and radioembolization or selective internal radiotherapy. A brief technical overview of embolotherapeutic modalities as well as supportive evidence for the treatment of most common primary and secondary liver tumors will be discussed in this review. Several potential future applications, including synergy with systemic therapy, interventional theranostics, and artificial intelligence will also be reviewed briefly.

show abstract

Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation

Abstract: TARE is safe and can be effective in patients with an intermediate or advanced stage HCC who are refractory to TACE. This treatment strategy has the potential to downstage to liver transplantation.

Cited by 20 publications

References 32 publications

Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update

Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update

Huge Hepatocellular Carcinoma Treated with Radical Hepatectomy after Drug-eluting Bead Transarterial Chemoembolization

Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions

Contact Info

Product

Resources

About